TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03704298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Administered as an IV infusion
Study: NCT04058314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini IV
Description: Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Eye
Description: Control eyes will receive an approved monofocal or toric IOL post cataract extraction
Study: NCT04055480

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop using standard rapid-acting insulin
Description: Closed-loop using standard rapid-acting insulin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop using faster insulin aspart
Description: Closed-loop using faster insulin aspart
Study: NCT00547261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR97225
Description: every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR97225
Description: every 3 weeks
Study: NCT03783702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 Mg (milligram) Oral Tablet
Description: Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 MG (milligram) Oral Tablet
Description: All patients will receive acetaminophen as the first-line analgesic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 MG (milligram) Oral Tablet
Description: All patients will receive acetaminophen as the first-line analgesic.
Study: NCT03239028

Intervention type: BEHAVIORAL
Intervention: Observational
Study: NCT02399475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone
Description: 200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone
Description: 200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
Study: NCT02088216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600mg po twice a day for 12 months

Intervention type: OTHER
Group type: OTHER
Intervention: On-demand treatment
Description: receive as-needed therapy
Study: NCT00843622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-nitrosamine smokefree tobacco product for oral use
Description: Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-tobacco, non-nicotine placebo product
Description: Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
Study: NCT04788199

Intervention type: OTHER
Intervention: Closure of mesenteric defects using glue
Description: Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
Study: NCT01283191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Incentives
Description: Vouchers for complying with target behavior of treadmill walking

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Control
Description: Education class
Study: NCT00606697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR205171
Description: 10 milligrams (mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW597599
Description: 15 mg
Study: NCT01383044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVL + carvedilol
Description: EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Description: carvedilol 6.25mg-12.5 mg per day
Study: NCT00594152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIIIT
Description: The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
Study: NCT03601338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin
Description: second generation low molecular weight Heparin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: multivitamins and routine antenatal follow up
Description: multivitamins and routine antenatal follow up
Study: NCT02788916

Intervention type: OTHER
Intervention: No Intervention
Study: NCT02025738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAGNET APPLICATION
Study: NCT00804973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 4 capsules, once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule
Description: 4 capsules, once
Study: NCT03624868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: See above description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: See above description
Study: NCT04097041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanomastoidectomy
Description: Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanomastoidectomy
Description: Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgery
Description: Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing.
Study: NCT00724958

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Not specified in the protocol.
Study: NCT03572582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab therapy combined with standard TACE treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed by using drug eluting beads
Study: NCT01301937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose
Study: NCT02751424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3342830
Description: A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3342830
Description: A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
Study: NCT03174158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy
Description: Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy
Description: Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: 12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: 12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
Study: NCT05359965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: Gentle and steady pressure (with or without supplemental oxygen) delivered to the airways of the lungs while subjects are sleeping.
Study: NCT02342509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
Study: NCT01720953

Intervention type: OTHER
Intervention: Mentalization Based Therapy
Description: Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
Study: NCT02025738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPROGRAMING
Study: NCT01519947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants received 50-250 mcg SC according to local label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants received 50-250 mcg SC according to local label
Study: NCT02921282

Intervention type: GENETIC
Intervention: Genotype dopamine
Description: Laboratory investigations of nicotine reinforcement

Intervention type: GENETIC
Intervention: Genotype dopamine
Description: Laboratory investigations of nicotine reinforcement
Study: NCT03985722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab and Trabectedin
Description: Dose escalation levels:~LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT.~LEVEL 0\*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1. \* Dose starting level is 0.~LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1.~LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1.~LEVEL 3\*\*: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1~\*\*In LEVEL 3, Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8). Then, the maintenance dose will be 15 mg/m2 for the rest of cycles.
Study: NCT01800955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)
Description: The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham placebo resistive capacitive diathermy treatment
Description: The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group
Study: NCT01029600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic capsular release
Description: Surgical division of thickened capsule in the shoulder
Study: NCT02921282

Intervention type: GENETIC
Intervention: Genotype cannabinoids
Description: Laboratory investigations of nicotine reinforcement

Intervention type: GENETIC
Intervention: Genotype cannabinoids
Description: Laboratory investigations of nicotine reinforcement
Study: NCT01029600

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distention with steroid
Description: Intraarticular distention with steroid, saline, contrast and local anaesthetic
Study: NCT01519947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants received 50-250 mcg SC according to local label
Study: NCT02303574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7986, oral solution, 1 to 50 mg/mL
Description: Starting dose in single ascending dose part: 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, oral solution
Description: Matching placebo
Study: NCT01582243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
Study: NCT03695289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iOTA SMI
Description: Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
Study: NCT04019821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine
Description: A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
Study: NCT02025738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NO ACTION
Study: NCT03974646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led self-management Program
Description: Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
Study: NCT03827577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal of primary and/or of all oligometastases
Description: Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-surgical LAT
Description: Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
Study: NCT04338022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Evobrutinib twice daily (BID) in DBTP.
Study: NCT01519947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants received 50-250 mcg SC according to local label